Differential expression of protein phosphatase type 1 isotypes and nucleolin during cell cycle arrest.
In the present study, we examined the expression and cytolocalization of protein phosphatase type 1 (PP1) isoforms and nucleolin in human osteoblastic cell line MG63 cells at two boundaries in the cell cycle. We treated MG63 cells with hydroxyurea and nocodazole to arrest the cells at the G(1)/S and G(2)/M boundaries, respectively. As judged from the results of Western blot analysis, PP1 isoforms were expressed differently at each boundary of the cell cycle. Nucleolin was also shown to have a different expression pattern at each boundary. In the hydroxyurea-treated cells, nucleolus-like bodies were bigger in size and decreased in number compared with those in asynchronized cells. However, the subcellular localization of PP1s and nucleolin was not changed. Anti-nucleolin antibody interacted with 110-kDa and 95-kDa proteins present in asynchronized cells and in the cells treated with hydroxyurea. Treatment of the cells with nocodazole decreased the level of the 95-kDa form of nucleolin. In the nocodazole-treated cells, it was impossible to distinguish the distribution of each protein. The phosphorylation status of nucleolin in the cell cycle arrested samples was examined by 2D-IEF-PAGE followed by Western blot analysis. In the case of asynchronized cells or hydroxyurea-treated ones, nucleolin was located at a basic isoelectric point (dephosphorylated status); whereas in the G(2)/M arrest cells, the isoelectric point of nucleolin shifted to an acidic status, indicating that nucleolin was phosphorylated. The present results indicate that PP1 and nucleolin were differently expressed at G(1)/S and G(2)/M boundaries of the cell cycle and acted in a different fashion during cell-cycle progression.
Morimoto
Hiroyuki
H
Department of Oral and Maxillofacial Anatomy, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto, Tokushima, Japan. morimoto@dent.tokushima-u.ac.jp
Ozaki
Akiko
A
Okamura
Hirohiko
H
Yoshida
Kaya
K
Amorim
Bruna Rabelo
BR
Tanaka
Hiroaki
H
Kitamura
Seiichiro
S
Haneji
Tatsuji
T
D002453:Cell Cycle / Q000187:drug effects*; D002478:Cells, Cultured; D019926:Cyclin B / Q000096:biosynthesis; D056744:Cyclin B1; D056741:Cyclin D; D016213:Cyclins / Q000096:biosynthesis; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D007527:Isoenzymes / Q000096:biosynthesis; D015739:Nocodazole / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000096:biosynthesis*; D010750:Phosphoproteins / Q000096:biosynthesis*; D054645:Protein Phosphatase 1; D054648:Protein Phosphatase 2; D016601:RNA-Binding Proteins / Q000096:biosynthesis*; D000097796:Nucleolin
D019926:Cyclin B; D056744:Cyclin B1; D056741:Cyclin D; D016213:Cyclins; D006918:Hydroxyurea; D007527:Isoenzymes; D015739:Nocodazole; D010749:Phosphoprotein Phosphatases; D010750:Phosphoproteins; D054645:Protein Phosphatase 1; D054648:Protein Phosphatase 2; D016601:RNA-Binding Proteins; D000097796:Nucleolin; C534699:CCNB1 protein, human; C517192:PPP2R2C protein, human; C517187:PPP1CA protein, human; C517102:PPP1CC protein, human